このエントリーをはてなブックマークに追加
ID 30544
JaLCDOI
フルテキストURL
著者
Takahashi, Isao Okayama University
Hara, Masamichi Okayama University
Adachi, Tomiro Okayama University
Takaoka, Kazuko Okayama University
Sakano, Makoto Okayama University
Lai, Miinyuh Okayama University
Kohi, Fumikazu Okayama University
Yorimitsu, Seiichi Okayama University
Tokioka, Masaaki Okayama University
Kitajima, Koichi Okayama University
Kimura, Ikuro Okayama University
Sanada, Hiroshi Okayama University
抄録

Twelve patients with refractory acute leukemia (7 patients with acute myelocytic leukemia and 5 patients with acute lymphocytic leukemia) were treated with a new anthracycline antibiotic, aclacinomycin-A (ACM). ACM was administrated by intravenous drip infusion at a dose of 20 mg/day for 7 or 14 days and this was repeated after at least 7 days. Four of 12 patients (33.3%) achieved a complete remission; 3 of 7 acute myelocytic leukemia (42.8%) and 1 of 5 acute lymphocytic leukemia (20.0%). The days required for achieving the complete remission ranged from 23 to 78 days (median: 61) and the total doses of ACM used from 180 to 500 mg (median: 310), and the durations of complete remission from 11 to 28+ weeks (median: 21+). The untoward effects on digestive organs, such as nausea, vomiting and anorexia, and hematological toxicities were frequently seen; however, they were controlled by supportive treatment. Alopecia was not observed. Arrythmia was recognized in one patient at the initiation of ACM infusion with complete remission without withdrawal of ACM. These results suggest that ACM is a potentially effective anthracycline antibiotic in the clinical management of acute leukemia.

キーワード
aclacinomycin-A
leukemia
chemotherapy
Amo Type
Brief Note
発行日
1980-11
出版物タイトル
Acta Medica Okayama
34巻
5号
出版者
Okayama University Medical School
開始ページ
349
終了ページ
354
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Sience KeyUT